SINGAPORE – November 29, 2011 – For the fourth time in six years, Quintiles has been named Asia Pacific Contract Research Organization of the Year by Frost & Sullivan, a leading business research and consulting firm, Quintiles announced today. The award, presented at the 2011 Frost & Sullivan Asia Pacific Best Practices Awards ceremony held today in Singapore, honors the CRO that exhibited the highest overall excellence across a broad range of categories.

“I’m proud that Quintiles has been recognized once again for excellence, and believe it reflects our continuing commitment to meet our customers changing needs,” said Anand Tharmaratnam, Senior Vice President and Head of Asia Markets. “Asia is the new frontier for drug development as Western companies seek to develop and register products here, and emerging Asia companies seek new global capabilities.

“Quintiles’ expertise and global reach allows us to help both groups capitalize on opportunities to bring new and better medicines to patients in need. We will continue to invest the region to further entrench the position of Quintiles as the drug developer of choice for global and local registration studies.”

In granting the award, Frost & Sullivan cited Quintiles’ top scores in five key areas: customer service; innovation; revenue and revenue growth; market share and market share growth; and growth strategy and implementation excellence.

Neha Koul, Healthcare Research Analyst, Frost & Sullivan Asia Pacific, said: “Quintiles is the clear market leader in the APAC CRO landscape. Its multiple growth strategies, cutting edge investments and exemplary client services make it well positioned to continue its growth.”

In 2011 alone Quintiles was named Best CRO in the Vaccine Industry Excellence Asia Awards; placed fourth in the prestigious InformationWeek 500 technology innovators list; and ranked 25th in the inaugural World’s Best Multinational Workplaces from the Great Place to Work® Institute. Quintiles opened its first Asia Pacific office (Tokyo) in 1993 and now has 4,000+ employees across 15 countries in Asia Pacific. In the past 12 months Quintiles has launched a consulting practice led by Christian Gabel, Vice President and Head of Quintiles Consulting, Asia, and has expanded the Strategic Drug Development team led by Amar Kureishi, Regional Chief Medical Officer, Asia.

Quintiles Asia Pacific has conducted 1,300 studies involving more than 9,000 sites and about 185,000 patients in the region, with the studies covering a wide range of therapeutic areas, including cardiovascular disease, oncology, neurology and infectious diseases.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.